prostate cancer: receiver operating characteristic
curves. J Urol 152:2031.
Catalona WJ, Hudson MA, Scardino PT, Richie JP,
Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL,
Kavoussi LR, Dalkin BL, Waters WB, MacFarlane
MT, and Southwick PC. 1994b. Selection of optimal
prostate specific antigen cutoffs for early detection of
prostate cancer: receiver operating characteristic
curves. J Urol 152:2037.
Charrier JP, Tournel C, Michel S, Dalbon P, and Jolivet
M. 1999. Two-dimensional electrophoresis of
prostate-specific antigen in sera of men with prostate
cancer or benign prostate hyperplasia. Electrophoresis
10:1075.
Collins GN, Lee RJ, McKelvie GB, Rogers ACN, and
Hehir M. 1993. Relationship between prostate specific
antigen, prostate volume and age in the benign
prostate. Br J Urol 71:445.
Cree IA and Kurbacher CM. 1997. Individualizing
chemotherapy for solid tumors—is there any alterna-
tive? Anticancer Drugs 8:541.
Crotty PL, Staggs RA, Porter PT, Killeen AA, and
McGlennen RC. 1994. Quantitative analysis in
molecular diagnostics. Hum Pathol 25:572.
Deutsch HF. 1991. Chemistry and biology of alpha-
fetoprotein. Adv Cancer Res 56:253.
Dropcho EJ. 1998. Neurologic paraneoplastic syndromes.
J Neurol Sci 153:264.
Faderl S, Talpaz M, Estrov Z, and Kantatjian HM. 1999.
Chronic myelogenous leukemia: biology and therapy.
Ann Intern Med 131:207.
Falanga A and Rickles FR. 1999. Pathophysiology of the
thrombophilic state in the cancer patient. Semin
Thromb Hemost 25:173.
Franks L. 1954. Latent carcinoma of the prostate. J Path
Bact 68:603.
Frizzera G, Wu CD, and Inghirami G. 1999. The useful-
ness of immunophenotypic and genotypic studies in
the diagnosis and classification of hematopoietic and
lymphoid neoplasms. An update. Am J Clin Pathol
111(Suppl 1):S13.
Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ,
Speizer FE, and Willett WC. 1994. A prospective
study of family history and the risk of colorectal
cancer. N Engl J Med 331:1669.
Giuffrida D and Gharib H. 1998. Current diagnosis and
management of medullary thyroid carcinoma. Ann
Oncol 9:695.
Gordon SG and Mielicki WP. 1997. Cancer procoagulant:
a factor X activator, tumor marker and growth factor
from malignant tissue. Blood Coagul Fibrinolysis
8:73.
Hammarström S. 1999. The carcinoembryonic antigen
(CEA) family: structures, suggested functions and
expression in normal and malignant tissues. Semin
Cancer Biol 9:67.
Hanahan D and Weinberg RA. 2000. The hallmarks of
cancer. Cell 100:57.
Hayes DF, Bast RC, Desch CE, Fritsch Jr H, Kemeny
NE, Jessup JM, Locker GY, Macdonald JS, Mennel
RG, Norton L, Ravdin P, Taube S, and Winn RJ.
1996. Tumor marker utility grading system: a frame-
work to evaluate clinical utility of tumor markers. J
Natl Cancer Inst 88:1456.
Hayes DF, Trock B, and Harris AL. 1998. Assessing the
clinical impact of prognostic factors: when is “statisti-
cally significant” clinically useful? Breast Cancer Res
Treat 52:305.
Hilz H, Noldus J, Hammerer P, Buck F, Luck M, and
Huland H. 1999. Molecular heterogeneity of free PSA
in sera of patients with benign and malignant prostate
tumors. Eur Urol 36:286.
Jass JR. 2000. Pathology of hereditary nonpolyposis
colorectal cancer. Ann N Y Acad Sci 910:62.
Jung K, Brux B, Lein M, Rudolph B, Kristiansen G,
Hauptmann S, Schnorr D, Loening SA, and Sinha P.
2000. Molecular forms of prostate-specific antigen in
malignant and benign prostatic tissue: biochemical and
diagnostic implications. Clin Chem 46:47.
Kadmon D, Weinberg AD, Williams RH, Pavlik VN,
Cooper P, and Migliore PJ. 1996. Pitfalls in interpret-
ing prostate specific antigen velocity. J Urol
155:1655.
Kahn SB. 1994. Neoplasia. In Noe DA and Rock, eds.
Laboratory medicine. The Selection and Interpretation
of Clinical Laboratory Studies.
Williams & Wilkins,
Baltimore.
Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM,
and Scardino PT. 1998. A preoperative nomogram for
disease recurrence following radical prostatectomy for
prostate cancer. J Natl Cancer Inst 90:766.
Kearney L. 1999. The impact of the new fish technologies
on the cytogenetics of haematological malignancies.
Br J Haematol 104:648.
Keren DF. 1999. Procedures for the evaluation of
monoclonal immunoglobulins. Arch Pathol Lab Med
123:126.
Ketter R, Zwergel T, Romanakis K, Unteregger G,
Ziegler M, Zang KD, and Wullich B. 1996. Selection
toward diploid cells in prostatic carcinoma derived cell
cultures. Prostate 28:364.
Kinzler KW and Vogelstein B. 1996. Lessons from
hereditary colon cancer. Cell 87:159.
Loda M. 1994. Polymerase chain reaction-based methods
for the detection of mutations in oncogenes and tumor
suppressor genes. Hum Pathol 25:564.
Lynch HT and de la Chapelle A. 1999. Genetic suscepti-
bility to non-polyposis colorectal cancer. J Med Genet
36:801.
Lynch HT, Fusaro RM, and Lynch JF. 1997. Cancer
genetics in the new era of molecular biology. Ann NY
Acad Sci 833:1.
Cancer
11-20
